Oncostrol 160 Tablet contains Megestrol acetate 160 mg, a synthetic progestin with antineoplastic and appetite-stimulating properties. It is primarily indicated for the palliative treatment of advanced breast cancer and endometrial carcinoma, as well as for the management of anorexia, cachexia, or significant weight loss associated with chronic illnesses such as cancer or AIDS. Megestrol exerts its therapeutic effects by modulating hormonal activity, thereby inhibiting the growth of hormone-dependent tumors and improving appetite and nutritional status in affected patients. Oncostrol 160 is administered orally, with dosage tailored according to the clinical condition and patient response. Common adverse effects may include fluid retention, thromboembolic events, hypertension, and gastrointestinal disturbances; therefore, caution is advised in patients with cardiovascular risk factors or thrombotic disorders. Regular monitoring of weight, electrolytes, and blood pressure is recommended during therapy. Oncostrol 160 should be used under strict medical supervision, considering potential drug interactions and contraindications such as known hypersensitivity to megestrol or progestins, active thromboembolic disease, or uncontrolled diabetes mellitus. This medication offers a valuable option in supportive cancer care, enhancing quality of life by addressing both tumor progression and associated metabolic complications.